Bispecific Antibodies | Joshua Richter, MD | ASH 2022

Prospective Evaluation of the Biology of Aggressive Myeloma Lesions After Induction | ASH 2022
Detecting Myeloma with Single Cell Sequencing | Scott Goldsmith, MD | ASH 2022
What to Look Forward to at ASH | Ola Landgren, MD, PhD | ASH 2022
(Guest Lecture): Relapsed Refractory Multiple Myeloma - Krina Patel, MD, MSc | RT Irvine, CA Nov 5, 2022
(Guest Lecture) November 2022 - Integrative Medicine: Ideas for Myeloma Treatment
(Guest Lecture): November 2022 - How Myeloma Frontline Therapy is Changing - Ajai Chari, MD
(Guest Lecture): November 2022 - CAR-T: Ready for Prime Time?
(Guest Lecture) November 2022 - Physiatry: A New Approach Incorporating Proven Ideas
CAR-T: Ready for Prime Time? - Jesus Berdeja, MD | RT Irvine, CA Nov 5, 2022
Moderated Discussion and Round Table Audience Q&A One | RT Irvine, CA Nov 5, 2022
Round Table Audience Q&A Two | RT Irvine, CA Nov 5, 2022
Physiatry: A New Approach Incorporating Proven Ideas - Jessica Cheng, MD | RT Irvine, CA Nov 5, 2022
HealthTree Coach Program Discussion | RT Irvine, CA Nov 5, 2022
Amrita Krishnan Leads Faculty Discussion | RT Irvine, CA Nov 5, 2022
Pushing Toward Tomorrow - Amrita Krishnan, MD, FACP | RT Irvine, CA Nov 5, 2022
Integrative Medicine: Ideas for Myeloma Treatment - Richard Lee, MD | RT Irvine, CA Nov 5, 2022
Relapsed Refractory Multiple Myeloma - Krina Patel, MD, MSc | RT Irvine, CA Nov 5, 2022
How Myeloma Frontline Therapy is Changing - Ajai Chari, MD | RT Irvine, CA Nov 5, 2022